| Code | CSB-RA004879MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to atibuclimab, targeting CD14, a glycosylphosphatidylinositol-anchored membrane protein and pattern recognition receptor expressed primarily on monocytes and macrophages. CD14 functions as a co-receptor for lipopolysaccharide (LPS) detection, playing a critical role in innate immune responses and inflammatory signaling pathways. Through its interaction with toll-like receptor 4 (TLR4), CD14 mediates cellular responses to bacterial endotoxins and is implicated in various inflammatory conditions, sepsis, atherosclerosis, and immune-mediated disorders. Dysregulated CD14 expression has been associated with chronic inflammatory diseases and altered immune homeostasis.
Atibuclimab represents a therapeutic monoclonal antibody designed to modulate CD14-mediated inflammatory responses. This biosimilar antibody provides researchers with a valuable tool for investigating CD14 biology, studying monocyte and macrophage function, exploring innate immune mechanisms, and evaluating potential therapeutic interventions in inflammation-related research models. The antibody enables detailed examination of CD14's role in pathogen recognition, cytokine production, and immune cell activation across various experimental systems.
There are currently no reviews for this product.